News & Events
Canadian FOP Family Conference |
|
Date: Thursday, June 12 and Friday, June 13, 2025
Location: Toronto
Registration: Coming soon!
Join us for this in-person Canadian FOP Family Meeting where we will meet our FOP medical experts located in Canada, including:
Information on Clinical Trials will be presented along with presentations from pharmaceutical companies such as Ipsen, Regeneron, Incyte, etc.
A detailed agenda will be released prior to the event.
Location: Toronto
Registration: Coming soon!
Join us for this in-person Canadian FOP Family Meeting where we will meet our FOP medical experts located in Canada, including:
- Dr. Angela Cheung, Toronto University Health
- Dr Peter Kannu, University of Alberta
- Dr. Clive Friedman, Board Certified Dentist, London, Ontario
- Dr. Christiaan Scott, University of Ottawa
Information on Clinical Trials will be presented along with presentations from pharmaceutical companies such as Ipsen, Regeneron, Incyte, etc.
A detailed agenda will be released prior to the event.
Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans progressiva
On Jan 24, 2022, Ipsen announced the Canada approval of Sohonos (palovarotene capsules). Indicated to reduce new bone formation in adults and children (8 years and above for females and 10 years and above for males) with FOP. Sohonos is approved for both chronic use, and for flare-ups. It is the first approval for Sohonos worldwide.
Sohonos is an oral, selective RARγ agonist developed as a treatment for people living with this debilitating ultra-rare genetic disorder. The treatment was acquired by Ipsen through the acquisition of Clementia Pharmaceuticals.
Sohonos is an oral, selective RARγ agonist developed as a treatment for people living with this debilitating ultra-rare genetic disorder. The treatment was acquired by Ipsen through the acquisition of Clementia Pharmaceuticals.
